Kümmel, S., & Schneeweiss, A. (2017). Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE). European journal of cancer, 84, . https://doi.org/10.1016/j.ejca.2017.06.037
Chicago Style (17th ed.) CitationKümmel, Sherko, and Andreas Schneeweiss. "Randomised, Open-label, Phase II Study Comparing the Efficacy and the Safety of Cabazitaxel Versus Weekly Paclitaxel Given as Neoadjuvant Treatment in Patients with Operable Triple-negative or Luminal B/HER2-negative Breast Cancer (GENEVIEVE)." European Journal of Cancer 84 (2017). https://doi.org/10.1016/j.ejca.2017.06.037.
MLA (9th ed.) CitationKümmel, Sherko, and Andreas Schneeweiss. "Randomised, Open-label, Phase II Study Comparing the Efficacy and the Safety of Cabazitaxel Versus Weekly Paclitaxel Given as Neoadjuvant Treatment in Patients with Operable Triple-negative or Luminal B/HER2-negative Breast Cancer (GENEVIEVE)." European Journal of Cancer, vol. 84, 2017, https://doi.org/10.1016/j.ejca.2017.06.037.